Clinical trials: Primary Open - Angle Glaucoma (POAG)
POAG, MIGS
Efficacy and Safety of iStent Inject and Inject W in the Management of Primary Open-angle Glaucoma
Primary open-angle glaucoma (POAG) is a chronic eye disease in which the only validated treatment is to lower intraocular pressure (IOP). It is the 2nd leading cause of blindness worldwide.
- Trial name
- EII (NCT05062668)
- Testing
- cataract operation and istent, cataract operation only
- Where
- France
- Volunteers
- 80 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Glaucoma, Primary Open Angle, Cataract
Investigate, Following Cataract Surgery With IOL in Conjunction With Intracanalicular Dexamethasone Insert
Randomized, controlled treatment with an intracanalicular dexamethasone (0.4mg) insert following cataract surgery with intraocular lens implant (IOL) combined with minimally invasive glaucoma surgery (MIGS), specifically iStent…
- Trial name
- NCT04465864
- Testing
- Intracanalicular Dexamethasone, 0.4 mg insert
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Wolstan and Goldberg Eye Associates
Pigmentary Glaucoma, Primary Open Angle Glaucoma
Autoimmune Dysregulation in Pigmentary Glaucoma
Based on these recent observations and findings in this new animal model of pigmentary glaucoma in the DBA/2J mouse, we propose that immune system abnormalities in the anterior chamber may play a possible role in the development…
- Conditions
- Pigmentary Glaucoma, Primary Open Angle Glaucoma, Cataract
- Trial name
- NCT00280345
- Testing
- Trabeculectomy, Trabeculectomy and cataract surgery, Cataract surgery
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- University of Oklahoma
Ocular Hypertension, Open Angle Glaucoma
CLN-0045: Safety, and Efficacy of OTX-TIC in Participants With Open Angle Glaucoma or Ocular Hypertension
To assess the safety, tolerability and efficacy of a single sustained release dose of OTX-TIC, a sustained release travoprost drug product, in subjects with primary open-angle glaucoma or ocular hypertension.
- Trial name
- NCT04360174
- Testing
- OTX-TIC
- Where
- 5 sites in United States
- Volunteers
- 19 people
- Sponsor
- Ocular Therapeutix, Inc.
Glaucoma
Culturing TM Cells From Primary Open-angle Glaucoma Patient Biopsies
In this study, the investigators will collect tissue from patients undergoing trabeculectomy for primary open-angle glaucoma treatment. This tissue would normally be discarded.
- Trial name
- NCT02151318
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- University of South Florida
Open Angle Glaucoma, Primary Open Angle Glaucoma
Topical Insulin for Glaucoma (TING2)
This study evaluates the safety and preliminary efficacy of topical sterile human insulin eye drops (EYED-002) in patients with open-angle glaucoma.
- Conditions
- Open Angle Glaucoma, Primary Open Angle Glaucoma, Low Tension Glaucoma, Pigmentary Glaucoma
- Trial name
- NCT07619482
- Testing
- EYED-002 Low Dose (721 U/mL topical insulin), EYED-002 High Dose (1442 U/mL topical insulin), EYED-002 (highest tolerated dose, 12-month)
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Stanford University
Glaucoma, Open-Angle, Ocular Hypertension
A Study of Lumigan® 0.01% in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
A study of Lumigan® 0.01% as administered in standard practice for patients with POAG or OHT. All treatment decisions, care and diagnostic procedures provided are at the discretion of the participating physicians according to…
- Trial name
- NCT01589510
- Testing
- bimatoprost 0.01% ophthalmic solution
- Where
- Austria
- Volunteers
- 419 people
- Sponsor
- Allergan
Primary Open Angle Glaucoma, Ocular Hypertension
Latanoprost Versus Tafluprost: 24-hour Intraocular Pressure (IOP)
Main objective is to compare the ability of Latanoprost 0.005% preservative-added ophthalmic solution versus Tafluprost 0.0015% preservative-free ophthalmic solution, both given once a day at the evening, in reducing 24-hour…
- Trial name
- SAF-24H-IOP (NCT01162603)
- Testing
- Goldmann and Perkins applanation tonometry, TAFLUPROST 0.0015% EYEDROPS, LATANOPROST 0.005% EYEDROPS
- Where
- 2 sites in Greece, Italy
- Volunteers
- 40 people
- Sponsor
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Primary Open-angle Glaucoma, Ocular Hypertension
Study of Brinzolamide and Timolol When Added to Travoprost in Primary Open-angle Glaucoma or Ocular Hypertension
The purpose of the study is to compare the efficacy and safety of Timolol 0.5% solution to Brinzolamide 1% each given twice daily when added to Travoprost 0.004% given each evening.
- Conditions
- Primary Open-angle Glaucoma, Ocular Hypertension, Pigment Dispersion Glaucoma
- Trial name
- NCT00372827
- Testing
- Brinzolamide 1% added to Travoprost 0.004%
- Where
- Germany
- Volunteers
- 245 people
- Sponsor
- Alcon Research
Primary Open Angle Glaucoma, Pseudoexfoliation Glaucoma
XEN Glaucoma Gel Stent Versus Trabeculectomy
Multicentric evaluation of best corrected visual acuity of the XEN implant versus classic trabeculectomy in open angle glaucoma subjects
- Conditions
- Primary Open Angle Glaucoma, Pseudoexfoliation Glaucoma, Pigmentary Dispersion Glaucoma
- Trial name
- NCT05439161
- Testing
- surgery
- Where
- Austria
- Volunteers
- 196 people
- Sponsor
- Prof. Dr. Herbert Reitsamer
Glaucoma, Open-Angle, Ocular Hypertension
A Study of Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension
This is a study of bimatoprost as initial, replacement, or adjunctive intraocular pressure (IOP)-lowering therapy in patients with primary open angle glaucoma and ocular hypertension.
- Trial name
- LOTUS (NCT02061683)
- Testing
- Bimatoprost 0.03%
- Where
- China
- Volunteers
- 263 people
- Sponsor
- Allergan
Primary Open Angle Glaucoma, Ocular Hypertension
An Open, Non-randomized Pilot Study on the Effect of Preservative Free Tafluprost (Saflutan® Augentropfen) in Patients With Ocular Hypertension or Primary Open Angle Glaucoma With an Uncontrolled Intraocular Pressure of 30 mmHg and More
Increased intraocular pressure (IOP) has been identified as the most important risk factor for the development and the progression of glaucoma.
- Trial name
- NCT01979913
- Testing
- Saflutan® 15 microgram/ml Augentropfen im Einzeldosisbehältnis
- Where
- Austria
- Volunteers
- 16 people
- Sponsor
- Dr. Anton Hommer
Primary Open-Angle Glaucoma, Unspecified Eye, Ocular Hypertension
Efficacy and Safety Outcomes of Optometrist Performed Selective Laser Trabeculoplasty (SLT)
To measure the efficacy and safety outcomes of SLT performed by optometrists.
- Trial name
- SLT (NCT04036214)
- Testing
- Selective Laser Trabeculoplasty
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Northeastern State University
Ocular Hypertension, Primary Open Angle Glaucoma
Glaucoma Adherence Study, Spain
The purpose of this study is to evaluate adherence to DuoTrav® when reinforced by the use of the Travalert™ Dosing Aid.
- Trial name
- GAS (NCT00680329)
- Testing
- Travoprost 0.004%/timolol 0.05% fixed combination eye drops (DuoTrav), Travalert Dosing Aid
- Where
- Spain
- Volunteers
- 55 people
- Sponsor
- Alcon Research
Primary Open Angle Glaucoma or Ocular Hypertension
A Study Assessing the Safety and Efficacy of DE-117 in Subjects With POAG or OH Who Are Non-/Low-responders to Latanoprost: FUJI Study
The purposes of this study are to investigate the effect of intraocular pressure lowering efficacy and safety of DE-117 ophthalmic solution in subjects with primary open-angle glaucoma or ocular hypertension who are…
- Trial name
- NCT02822742
- Testing
- DE-117 ophthalmic solution, Latanoprost ophthalmic solution 0.005%
- Where
- Japan
- Volunteers
- 26 people
- Sponsor
- Santen Pharmaceutical Co., Ltd.
Glaucoma, Open-Angle
Valuation of the Antioxidant and Neuroprotective Effects of CoQ10-MINIACTIVES® (COQUN® OS) in Patients Affected by Primary Open Angle Glaucoma
This is a randomized, double blind study with competitive enrolment, aimed to enroll a total of 70 patients with a diagnosis of primary open angle glaucoma (POAG).
- Trial name
- NCT04038034
- Testing
- CoQ10- MINIACTIVES
- Where
- 2 sites in Italy
- Volunteers
- 70 people
- Sponsor
- VISUfarma SpA
Primary Open-Angle Glaucoma (POAG)
MEXIDOL® Sequential Therapy of Patients With Primary Open-angle Glaucoma (POAG)
Hypothesis: The use of neurocytoprotectors helps restore the functional activity of mitochondria, improve the nervous activity of the retina and optic nerve, and stabilize the glaucomatous process.
- Trial name
- NCT06437639
- Testing
- Mexidol
- Where
- Russia
- Volunteers
- 80 people
- Sponsor
- Pharmasoft
Exfoliation Syndrome, Primary Open Angle Glaucoma
Imaging Lens Deposits in Exfoliation Syndrome
The purpose of this study is to use a special eye imaging technique, anterior segment optical coherence tomography (AS-OCT), to image the lens (the curved, transparent part of the eye that helps you to see clearly by directing…
- Conditions
- Exfoliation Syndrome, Primary Open Angle Glaucoma, Cataracts
- Trial name
- NCT02042703
- Testing
- anterior segment OCT
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Duke University
Sleep Apnea, Obstructive, Primary Open-angle Glaucoma
IOP Fluctuations in Patients With Sleep Apnea With or Without Primary Open Angle Glaucoma Using Positive Airway Pressure
Sleep apnea is characterized by repetitive episodes of decreased or interrupted airflow in the upper airways during sleep. Obstructive sleep apnea syndrome (OSAS) is the most common sleep-related breathing disorder and is…
- Trial name
- NCT01560975
- Testing
- SENSIMED Triggerfish®
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Sensimed AG
Ocular Surface Disease, Primary Open Angle Glaucoma
Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting
The primary objective of this study is to assess the effectiveness of Tafluprost / Timolol in controlling ocular hypertension, as measured by mean change in intra-ocular pressure (IOP) from baseline to after 6 months of treatment…
- Trial name
- NCT04828057
- Testing
- Tafluprost, timolol maleate
- Where
- Taiwan
- Volunteers
- 50 people
- Sponsor
- Santen Pharmaceutical (Taiwan) Co., LTD